Women are at risk championing heart disease and heart attacks, just like men. In fact, heart disease is the leading cause of death among women over 65. American women are 4 to 6 times more likely to die because of problems with heart than because of breast cancer. Heart disease murder also more women after their 60s than all cancers combined. Women develop heart problems later in life than men -- typically 7 or 8 years later. However, close to approximate age of 65, a woman's chance is nearly the same as a man's.

Women are less likely to pull through heart assails than men. No one knows why. It may be that women don't look for or receive necessary treatment as soon as men do. Or it may be since women's smaller hearts and blood vessels are more simply damaged.

Doctors are working on to find answers to these questions. There's no question, however, that it is vital to prevent problems with heart before they start. Representing both men and women, the biggest factors that influence the development of heart diseases are smoking, high blood pressure, elevated cholesterol, family history and age. Take a moment to gaze at your lifestyle, family history and your general health.

With this information, you and your family doctor can assess your risk and make a plan to avoid potential problems. Although you can't discharge much about your kinsfolk history or your age, you can make lifestyle changes to shun many of the other risk piece.

Don' t smoke. Smoking is a major risk factor for heart disease in women. Half of the heart attacks in women under 50 are related to smoking. If you drop smoking, you can drop your risk of heart attack by 1 third within 2 years. Women who smoke and use birth control pills increase their risk even more. There are a variety of products to benefit you in your refusal to sigarettes. You may want to try using nicotine skin patches or nicotine gum. There are also prescription medicines to hand that can help you to quit smoking. Ask your physician the best way for you to quit smoking.

Breathing smoke from someone else's cigarettes is further malicious for your heart and lungs. If you live with someone who smokes, encourage him or her to quit.

Control your blood pressure. Treating high blood pressure can lower your risk of heart attack and stroke. Losing weight, exercising regularly and eating a healthy diet are all ways to help bridle high blood pressure.

Reducing the amount of salt you consume will also help. If this doesn't decrease your blood pressure, your doctor may recommend medicine for you to take. Control your cholesterol level. If you don't know your level, inquire your doctor to check it. Diet is a key part of lowering high cholesterol levels. However, some people have to take remedy in addition to diet and exercise. Maintain a healthy weight.

Extra weight puts strain on your heart and arteries. Exercise and a low-fat diet can help you solve this problem. Being overweight means you have a higher peril for indefinite other health problems, especially diabetes, high blood pressure and heart disease. If you're overweight, chatter to your doctor about a safe and effective course of action to lose weight.

Exercise regularly. Remember, your heart is a muscle. It needs regular exercise to be in shape. Aerobic exercise, such as brisk walking, swimming, jogging or biking, presents your heart the best workout. You can also exercise appropriateness equipment such as exercise bicycles, treadmills and ski machines when exercising indoors.

Finding a companion for exercising may make it easier and safer for you to exercise often. You should exercise at least 30 to 60 minutes, 4 to 6 times a week. Talk to your doctor before starting an exercise program.

Eat a low-fat diet. Keep fat calories to 30% or less of the complete calories you eat during a day and avoid saturated fat (in meats and coconut oil). Information is available to help you make healthy choices. For example, food labels list nutrition information, including fat calories, various cookbooks have heart-healthy recipes, and some restaurants attend to low-fat dishes.

Take care of diabetes. Whether you have diabetes, universal exercise, weight control, a low-fat nutrition and regular visits to your doctor are important. If you have to take medicine for diabetes, be certain to accept it exactly as your doctor tells you to.

Be aware of chest pain. Be sure to conjunction your doctor immediately if you suffer from malaise in your chest, shoulder, neck or jaw. Also inform your doctor if you experience shortness of breath or nausea that comes on quickly. If you are having a heart attack, the faster you can get to the hospital, the less your heart will be damaged. Every second counts.

And of course know your family history. Having a father or brother with heart disease before they are 55, or a mother or sister with heart disease beforehand age 65, are factors that contribute to heart disease. Inform your doctor about your family history.

Approximately 180,000 patients--both women and men--are diagnosed with breast cancer every year, and 40,000 persons die each year from it. Breast cancer is the primary cause of death in women superannuated 44-50 years. The whole 5-year survival rate is 60%, but if caught early, the degree increases to 80%.

Bosom Cancer Oncology Because of the hovering closeness of breast cancer and the aesthetic and symbolic of symbolical value invested in the breast, breast cancer has always been a source of severe distress to patients and their families.

For the duplicate reasons, breast cancer research has increased dramatically during the latest 2 decades, resulting in particular progress in our kind of the disease and in new, more unwasteful and less poisonous treatments. Breast Cancer Plastic Surgery Of American women, 13% will be diagnosed with breast cancer in their lifetimes, making it the most common nonskin cancer among women.

In addition, more than 3% will die from the disease. Breast cancer has surpassed lung cancer as the leading cause of cancer curtains in women worldwide, accounting for more than 400,000 passing per year. In the United States, breast cancer trails only lung cancer as the second most frequent cause of cancer death in women. In 2002, more than 1.15 million original cases were diagnosed worldwide.

More than 200,000 of these death cases were in the United States alone. With early detection, intervention and postoperative treatment breast cancer mortality has decreased. The use of mammography for screening has chiefly contributed to early detection; although its use has resulted in a minor increase in among in situ cancers detected.

Healthcare Professional: General Public: ZymoGenetics, Inc. NASDAQ:ZGEN) announced that the company has initiated Episode 2 testing of Interleukin 21 (IL-21) in combination with Nexavar(R) (sorafenib) tablets in patients with modern renal chamber cancer.

The Phase 2 study is part of a Phase 1 2 clinical check and will examine patients treated with the maximum tolerated potion identified in the recently completed Leaf 1 dose escalation phase.

We're encouraged by the fruit of the Page 1 parcel of this trial and are convinced that IL-21 in combination with Nexavar deserves further probation in renal apartment cancer," said Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer of ZymoGenetics. In Event 2, we'll continue to evaluate the tolerability and anti-tumor activity of this combination therapy in patients with dilatory stage renal cell cancer."

The leading objective of the open label multi-center Phase 2 glance at is to characterize aegis of IL-21 with Nexavar at the recommended dose; a secondary objective is to assess anti-tumor activity, which will be assessed by evaluating tumour response and circuit free survival. The trial is expected to enroll approximately 30 patients.

The recite is evaluating the combination in patients with pleasant cell carcinoma, which accounts for 85% of all renal cell tumors.

Results from the Phase 1 Trial with IL-21 and Nexavar Interim results from the Sheet 1 trial of IL-21 in combination with Nexavar in patients with renal cell cancer were presented in October 2007 at the AACR-NCI-EORTC International Conference.

That data indicated that the combination of IL-21 and Nexavar is well tolerated, with a toxicity profile collateral to published toxicities of each agent alone. Opening evidence of anti-tumor activity was also documented in the majority of the patients treated in Period 1. There will be an estimated 51,190 contemporary crate of renal cell carcinoma in the U.S. 2007.

It is estimated that renal cubicle carcinoma testament result in approximately 19,600 deaths in the U.S. Renal cell carcinoma render a reckoning for approximately 2% of cancers world wide. There is a clear need for new and improved therapies for renal cell cancer.

IL-21 in Set with Tyrosine Kinase Inhibitors Because tyrosine kinase inhibitors (TKIs) such as Nexavar and SutentВ® (Sunitinib) inhibit the growth of tumor cells and act on the underlying vasculature, and IL-21 activates the unaffected method to target slaughter of tumor cells, the two remedial programme may provide additive effects.

Treatment with a TKI may make cancer cells more sensitive to natural killer or T cell mediated killing after activation with IL-21.

Preclinical analysis conducted by ZymoGenetics of TKIs and IL-21 found that IL-21 had additive anti-tumor outcome when combined with a TKI in a renal cell cancer model. Previous clinical studies with IL-21 alone shown that IL-21 is an full cytokine that can be administered in an outpatient regimen.

Effect from a Stage 1 study presented at the American Homeland of Clinical Oncology (ASCO) 2006 annual meeting showed that IL-21 administration was tolerable in an outpatient setting and reductions in tumor size were observed in several patients. Available clinical data aid further clinical subject of IL-21 as a new restorative go-between for the treatment of cancer.

Approximately IL-21 Endogenous IL-21 has potent organic activity in regulating key classes of immune cells, including cytotoxic T cells and commonplace killer cells. These cell class frisk important roles in eliminating malignant and infected cells.

Based upon the knack of IL-21 to hold back tumor growth in a number of being models, ZymoGenetics is developing a recombinant figure of IL-21 representing the treatment of cancer, initially in metastatic melanoma and renal cell carcinoma and has retained commercialization rights championing IL-21 in North America. The company licensed commercialization rights outside of North America to Novo Nordisk A S. About ZymoGenetics ZymoGenetics creates narration protein drugs with the potential to significantly help patients fight their diseases.

The business is developing a contrasting pipeline of product aspirant that are moving into and through clinical development. These office-seeker chiefly span a wide array of clinical opportunities that include bleeding, autoimmune and viral diseases and cancer.

ZymoGenetics intends to commercialize these product candidates through interior development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio.